Localization of Pulmonary Ground-Glass Opacities with Folate Receptor–Targeted Intraoperative Molecular Imaging

Predina, Jarrod D.; Newton, Andrew D.; Corbett, Christopher; Xia, Leilei; Sulyok, Lydia Frenzel; Shin, Michael; Deshpande, Charuhas; Litzky, Leslie A.; Barbosa, Eduardo J. Mortani; Kucharczuk, John C.; Singhal, Sunil

doi:10.1016/j.jtho.2018.03.023

Cited by 25 publications

(28 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this trial, there were no drug-related adverse events observed perioperatively or within 30 days postoperatively (20). Sixteen of 21 tumors with GGO displayed lesion-specific fluorescence during NIR imaging, and the depth from the pleural surface was the sole determinant for the successful detection of lesions by intraoperative molecular imaging.…”

mentioning

confidence: 73%

See 1 more Smart Citation

Intraoperative molecular imaging—a bright navigator for thoracic surgeons in the era of limited resection

Suda

2018

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

mentioning

confidence: 73%

“…Predina and his colleagues have very recently published the data of intraoperative molecular imaging using OTL0038 for pulmonary small nodules with GGO in the Journal of Thoracic Oncology (20). This study recruited 20 patients with 21 pulmonary tumors, comprising nine pure GGOs and 12 GGOs with a solid component, which were suspicious for lung neoplasms.…”

mentioning

confidence: 99%

Intraoperative molecular imaging—a bright navigator for thoracic surgeons in the era of limited resection

Suda

2018

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

“…[19][20][21] First, the initial experience showed that FR-targeted IMI was successful not only for adenocarcinomas but also for ground glass opacities, a potential precursor for malignant lung adenocarcinoma, and a rapidly growing problem in the United States and Asia. 22 The second finding from the pilot studies was that IMI combined with PET was superior in detecting and locating tumors for removal; in fact, IMI was better than PET for locating nodules <1 cm. 23 Finally, despite theoretical specificity for lung adenocarcinomas, lung squamous cell carcinomas were also sensitive to OTL38 because of off-target effects on FR-beta positive tumor-associated macrophages.…”

Section: Folate Receptor Alpha For Lung Adenocarcinomamentioning

confidence: 96%

Review of clinical trials in intraoperative molecular imaging during cancer surgery

et al. 2019

Self Cite

View full text Add to dashboard Cite

Most solid cancers are treated by surgical resections to reduce the burden of disease. Surgeons often face the challenge of detecting small areas of residual neoplasm after resection or finding small primary tumors for the initial resection. Intraoperative molecular imaging (IMI) is an emerging technology with the potential to dramatically improve cancer surgery operations by allowing surgeons to better visualize areas of neoplasm using fluorescence imaging. Over the last two years, two molecular optical contrast agents received U.S. Food and Drug Administration approval, and several more drugs are now on the horizon. Thus a conference was organized at the University of Pennsylvania to bring together oncologic surgeons from different specialties to discuss the current clinical status of IMI trials with a specific focus on phase 2 and phase 3 studies. In addition, phase 1 and experimental trials were also discussed briefly, to highlight other novel techniques. Our review summarizes the discussions from the conference and delves into the types of cancers discussed, different contrast agents in human trials, and the clinical value being studied.

show abstract

“… 22 This molecular imaging technology used in cancer surgery mainly focuses on breast and hollow viscus, such as the respiratory and gastrointestinal tracts. 23 , 24 , 25 Optical molecular imaging can specifically show the pathological process related to tumorigenesis and provide real-time macroscopic imaging of tumor tissue in vivo . Therefore, it could be used to improve the quality of NMIBC management, such as detection of small or occult tumor lesions and evaluation of the status of surgical margin and depth of tumor invasion during tumor resection.…”

Section: Main Textmentioning

confidence: 99%

Endoscopic Molecular Imaging plus Photoimmunotherapy: A New Strategy for Monitoring and Treatment of Bladder Cancer

Yang

Liu

Yang

2020

Molecular Therapy - Oncolytics

View full text Add to dashboard Cite

Due to the high recurrence and progression rate of non-muscle invasive bladder cancer after transurethral resection of bladder tumor, some new optical imaging technologies have arisen as auxiliary imaging modes for white light cystoscopy to improve the detection rate of small or occult tumor lesions, such as photodynamic diagnosis, narrow-band imaging, and molecular imaging. White light cystoscopy is inadequate and imperfect for bladder cancer detection, and thus residual tumors or coexisting flat malignant lesions, especially carcinoma in situ , would be ignored during conventional resection. The bladder, a hollow organ with high compliance, provides an ideal closed operation darkroom for endoscopic molecular imaging free from interference of external light sources. Also, intravesical instillation of a molecular fluorescent tracer is simple and convenient before surgery through the urethra. Molecular fluorescent tracer has high sensitivity and specificity to tumor cells, and its mediated molecular imaging allows small or occult tumor lesion detection while minimizing false-positive results. Meanwhile, endoscopic molecular imaging provides a real-time and dynamic image during surgery, which helps urologists to perform high-quality and complete tumor resection through accurate judgment of tumor boundaries and depth of invasion. Photoimmunotherapy is a novel molecular targeted therapeutic pattern of photodynamic therapy that kills malignant cells selectively and minimizes the cytotoxicity to normal tissues. The combination of endoscopic molecular imaging and photoimmunotherapy used in initial treatment may avoid the need of repeat transurethral resection in strictly selected patients and improve oncological outcomes such as recurrence-free survival and overall survival after operation.

show abstract

Localization of Pulmonary Ground-Glass Opacities with Folate Receptor–Targeted Intraoperative Molecular Imaging

Cited by 25 publications

References 14 publications

Intraoperative molecular imaging—a bright navigator for thoracic surgeons in the era of limited resection

Intraoperative molecular imaging—a bright navigator for thoracic surgeons in the era of limited resection

Review of clinical trials in intraoperative molecular imaging during cancer surgery

Endoscopic Molecular Imaging plus Photoimmunotherapy: A New Strategy for Monitoring and Treatment of Bladder Cancer

Contact Info

Product

Resources

About